Concepts (72)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Transplantation | 7 | 2023 | 120 | 2.220 |
Why?
|
| Pancreas Transplantation | 3 | 2023 | 16 | 1.800 |
Why?
|
| Cell-Free Nucleic Acids | 3 | 2023 | 12 | 1.790 |
Why?
|
| Organ Transplantation | 2 | 2022 | 30 | 1.570 |
Why?
|
| Graft vs Host Disease | 2 | 2022 | 51 | 1.510 |
Why?
|
| Graft Rejection | 5 | 2023 | 63 | 0.890 |
Why?
|
| Tissue Donors | 4 | 2023 | 77 | 0.730 |
Why?
|
| Kidney Failure, Chronic | 2 | 2020 | 151 | 0.720 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2023 | 189 | 0.690 |
Why?
|
| Patient Compliance | 1 | 2020 | 145 | 0.640 |
Why?
|
| Immunosuppressive Agents | 2 | 2020 | 122 | 0.460 |
Why?
|
| Islets of Langerhans Transplantation | 2 | 2021 | 2 | 0.380 |
Why?
|
| Arteriovenous Shunt, Surgical | 2 | 2022 | 17 | 0.380 |
Why?
|
| C-Peptide | 2 | 2023 | 6 | 0.380 |
Why?
|
| Humans | 16 | 2023 | 26049 | 0.340 |
Why?
|
| Pancreas | 2 | 2023 | 26 | 0.260 |
Why?
|
| Transplant Recipients | 2 | 2023 | 22 | 0.260 |
Why?
|
| Retrospective Studies | 7 | 2022 | 3305 | 0.250 |
Why?
|
| Pancreatic Elastase | 1 | 2023 | 5 | 0.220 |
Why?
|
| Liver Transplantation | 2 | 2014 | 65 | 0.210 |
Why?
|
| Weight Gain | 1 | 2023 | 61 | 0.210 |
Why?
|
| Aneurysm | 1 | 2022 | 9 | 0.200 |
Why?
|
| Arteriovenous Fistula | 1 | 2022 | 11 | 0.200 |
Why?
|
| Islets of Langerhans | 1 | 2021 | 3 | 0.200 |
Why?
|
| Adolescent | 3 | 2020 | 2064 | 0.190 |
Why?
|
| Young Adult | 3 | 2020 | 1853 | 0.190 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2021 | 22 | 0.180 |
Why?
|
| Surgical Instruments | 1 | 2020 | 21 | 0.180 |
Why?
|
| Health Care Costs | 1 | 2020 | 72 | 0.170 |
Why?
|
| Biological Products | 1 | 2021 | 43 | 0.170 |
Why?
|
| Suture Techniques | 1 | 2020 | 146 | 0.170 |
Why?
|
| Time Factors | 4 | 2022 | 1364 | 0.150 |
Why?
|
| Adult | 5 | 2020 | 7367 | 0.150 |
Why?
|
| Prognosis | 1 | 2020 | 750 | 0.150 |
Why?
|
| Prostatic Neoplasms | 1 | 2017 | 89 | 0.130 |
Why?
|
| Middle Aged | 4 | 2020 | 8511 | 0.130 |
Why?
|
| Aged | 4 | 2020 | 8719 | 0.130 |
Why?
|
| Male | 6 | 2020 | 14025 | 0.130 |
Why?
|
| Liver Cirrhosis | 1 | 2014 | 42 | 0.120 |
Why?
|
| Female | 5 | 2020 | 14411 | 0.110 |
Why?
|
| Treatment Outcome | 4 | 2022 | 3293 | 0.110 |
Why?
|
| Graft Survival | 2 | 2014 | 92 | 0.110 |
Why?
|
| Rectus Abdominis | 1 | 2013 | 5 | 0.110 |
Why?
|
| Abdominal Wall | 1 | 2013 | 6 | 0.110 |
Why?
|
| Surgical Flaps | 1 | 2013 | 50 | 0.100 |
Why?
|
| Vascular Patency | 2 | 2022 | 12 | 0.100 |
Why?
|
| Child, Preschool | 2 | 2013 | 589 | 0.090 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 4674 | 0.090 |
Why?
|
| Renal Dialysis | 2 | 2022 | 107 | 0.090 |
Why?
|
| Insulin | 2 | 2021 | 76 | 0.080 |
Why?
|
| Risk Factors | 2 | 2022 | 2246 | 0.080 |
Why?
|
| Ireland | 1 | 2009 | 3 | 0.080 |
Why?
|
| Child | 2 | 2013 | 1229 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 315 | 0.080 |
Why?
|
| Survival Rate | 1 | 2009 | 321 | 0.070 |
Why?
|
| Allografts | 2 | 2020 | 220 | 0.070 |
Why?
|
| Incidence | 2 | 2021 | 714 | 0.070 |
Why?
|
| Follow-Up Studies | 1 | 2009 | 1713 | 0.060 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2022 | 18 | 0.050 |
Why?
|
| Transplantation, Heterologous | 1 | 2021 | 16 | 0.050 |
Why?
|
| Costs and Cost Analysis | 1 | 2021 | 34 | 0.050 |
Why?
|
| Cost Savings | 1 | 2020 | 30 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 125 | 0.040 |
Why?
|
| Kidney | 1 | 2021 | 155 | 0.040 |
Why?
|
| Prostate-Specific Antigen | 1 | 2017 | 13 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2017 | 622 | 0.030 |
Why?
|
| United States | 1 | 2021 | 1981 | 0.030 |
Why?
|
| Waiting Lists | 1 | 2014 | 15 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2020 | 862 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2014 | 235 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2014 | 325 | 0.030 |
Why?
|
| Infant | 1 | 2013 | 522 | 0.020 |
Why?
|